Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 11TCr 6.85Cr 6.14Cr 5.64Cr 5.11Cr 9.56Cr 650.58Cr 9.74Cr 67Cr 27Cr 342.23Cr 26Cr 25Cr 1.08TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 34TCr 22Cr 20Cr 18Cr 16Cr 31Cr 2.08TCr 31Cr 214.89Cr 86Cr 1.09TCr 82Cr 80Cr 3.45TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
06/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+0.38%
1 week-3.33%
1 month-6.12%
3 months-15.81%
6 months-20.18%
Current year-33.92%
1 week 1,290
Extreme 1290
1,390
1 month 1,290
Extreme 1290
1,580
Current year 1,290
Extreme 1290
2,130
1 year 1,290
Extreme 1290
2,300
3 years 595.5
Extreme 595.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-3.33%-18.18%+94.78% 6.85Cr
+3.19%+11.31%+64.28%+155.66% 1,26300Cr
-0.73%+3.56%+44.65%+83.74% 66TCr
+1.41%+3.24%+35.25%+106.98% 52TCr
-1.30%+0.33%+53.29%+67.04% 39TCr
+2.18%+2.93%+73.90%+45.38% 37TCr
-1.48%+3.22%+32.24%+55.42% 31TCr
-1.15%+7.50%+11.76%+33.35% 29TCr
+1.15%+6.09%+56.15%+78.66% 25TCr
+3.06%+9.38%+42.48%+112.84% 21TCr
Average +0.34%+5.19%+39.58%+83.38% 42.62TCr
Weighted average by Cap. +0.39%+6.60%+50.08%+98.71%

Financials

2024 2025
Net sales 9.18TCr 5.97Cr 5.35Cr 4.92Cr 4.46Cr 8.33Cr 566.7Cr 8.48Cr 59Cr 24Cr 298.1Cr 22Cr 22Cr 940.11Cr 13TCr 8.24Cr 7.38Cr 6.79Cr 6.15Cr 11Cr 782.36Cr 12Cr 81Cr 32Cr 411.54Cr 31Cr 30Cr 1.3TCr
Net income 2.38TCr 1.55Cr 1.39Cr 1.28Cr 1.16Cr 2.16Cr 147.21Cr 2.2Cr 15Cr 6.11Cr 77Cr 5.82Cr 5.69Cr 244.21Cr 308.78Cr 20.08L 17.98L 16.54L 14.99L 28.01L 19Cr 28.54L 1.97Cr 79.18L 10Cr 75.35L 73.74L 32Cr
Net Debt 13TCr 8.69Cr 7.78Cr 7.16Cr 6.49Cr 12Cr 825.09Cr 12Cr 85Cr 34Cr 434.02Cr 33Cr 32Cr 1.37TCr 23TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 147.57Cr 59Cr 750.29Cr 56Cr 55Cr 2.37TCr
Projected Income Statement - Annual - Laboratorios Richmond S.A.C.I.F.
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
30/26/30 ARS 1,305.00 +0.38% 693
29/26/29 ARS 1,300.00 -5.80% 982
28/26/28 ARS 1,380.00 +6.98% 784
27/26/27 ARS 1,290.00 -2.27% 993
26/26/26 ARS 1,320.00 -2.22% 407
  1. Stock Market
  2. Stocks
  3. RICH Stock